Factors Associated with Clinical Outcomes of Differentiated Thyroid Cancer Following Radioiodine Therapy in Tanzania
Cancer Research Journal
Volume 7, Issue 3, September 2019, Pages: 73-78
Received: Jun. 3, 2019; Accepted: Jul. 2, 2019; Published: Jul. 23, 2019
Views 94      Downloads 18
Authors
Lulu Lunogelo Sakafu, Department of Clinical Oncology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
Teddy Frank Mselle, School of Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
Julius David Mwaiselage, Department of Clinical Oncology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
Khamza Kibwana Maunda, Department of Clinical Oncology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
Katherine Van Loon, Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, USA
Bouyoucef Salah Eddin, Department of Nuclear Medicine, CHU Bab El Oued University, Algiers, Algeria
Article Tools
Follow on us
Abstract
Background: Thyroid cancer is the most common endocrine type of malignancy, accounting for 1-5% of all cancers worldwide. Most of the differentiated thyroid cancers are asymptomatic. Surgery is the mainstay of management to be followed by radioactive iodine (RAI). RAI accessibility is still a challenge in most developing countries including Tanzania. The aim of this study was to determine factors affecting the clinical outcome of patients with differentiated thyroid cancer (DTC) following RAI treatment in a resource limited setting. Methods: This was a prospective cohort study carried out from 2014 to 2018 at the Ocean Road Cancer Institute, in Tanzania. A total of 52 histologically proven differentiated thyroid cancer patients post- near or total thyroidectomy were recruited. All patients received RAI therapy until ablation was achieved, were maintained on thyroxine suppression dose, and were followed for two years. Results: A total of 52 differentiated thyroid cancer patients were recruited after surgery by convenience sampling. The median age of patients was 46 years (range 17-77), and 87% (n=45) were female. Distant metastases were detected in 60% of patients (n=20) at initial presentation. The most common clinical presentation was a neck mass without compression symptoms (85%). Analysis at the end of two years revealed that female gender, clinical-pathological presentation, and the absence of distant metastasis(es) at diagnosis and amount of RAI received, contributed significantly to improved outcome. Conclusion: In a limited resource setting, the outcome of DTC patients post RAI therapy can be improved by early diagnosis hence improving clinical outcome.
Keywords
Radioiodine Therapy, Thyroid Cancer, Tanzania
To cite this article
Lulu Lunogelo Sakafu, Teddy Frank Mselle, Julius David Mwaiselage, Khamza Kibwana Maunda, Katherine Van Loon, Bouyoucef Salah Eddin, Factors Associated with Clinical Outcomes of Differentiated Thyroid Cancer Following Radioiodine Therapy in Tanzania, Cancer Research Journal. Vol. 7, No. 3, 2019, pp. 73-78. doi: 10.11648/j.crj.20190703.11
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Brown RL, de Souza JA, Cohen EE. Thyroid cancer: burden of illness and management of disease. J Cancer. 2011; 2: 193–9.
[2]
Iarc. IA for R on CWHO. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Globocan. 2012.
[3]
Schlumberger MJ. Papillary and Follicular Thyroid Carcinoma. N Engl J Med. 1998; 338 (5): 297–306.
[4]
Htwe TT, Hamdi MM, Swethadri GK, Wong JOL, Soe MM, Abdullah MS. Incidence of thyroid malignancy among goitrous thyroid lesions from the Sarawak General Hospital 2000-2004. Singapore Med J. 2009; 50 (7): 724–8.
[5]
Feldt-Rasmussen U. Iodine and Cancer. Thyroid. 2001; 11 (5): 483–6.
[6]
Andrews W, Kaiser DL. ThyroidCancer: Some BasicConsiderations. 1983; 33 (2): 87–97.
[7]
Handkiewicz-Junak D, Wloch J, Roskosz J, Krajewska J, Kropinska A, Pomorski L, et al. Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer. J Nucl Med [Internet]. 2007; 48 (6): 879–88. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17536106
[8]
Manel J, Blesa G, Pulido EG, Pulla MP, Candel VA, Bautista J, et al. Old and New Insights in the Treatment of Thyroid Carcinoma. 2010; 2010 (Table 1).
[9]
Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. CLINICAL REVIEW 170 A Systematic Review and Metaanalysis of the Effectiveness of Radioactive Iodine Remnant Ablation for Well-Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2004; 89 (8): 3668–76.
[10]
Silberstein EB, Alavi A, Balon HR, Clarke SEM, Divgi C, Gelfand MJ, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med [Internet]. 2012 Oct [cited 2014 Oct 13]; 53 (10): 1633–51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22787108
[11]
Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19: 1167–214.
[12]
Mazzaferri EL, Kloos RT. CLINICAL REVIEW 128 Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer. 2001; 86 (4): 1447–63.
[13]
Passler C, Scheuba C. Prognostic factors of papillary and follicular thyroid cancer: differences in an iodine-replete endemic goiter region. Endocrine-Related … [Internet]. 2004 [cited 2015 Jul 22]; 131–9. Available from: http://erc.endocrinology-journals.org/content/11/1/131.short
[14]
Wachter W, Mvungi M, Konig A, Pickardt CR, Scriba PC. Prevalence of goitre and hypothyroidism in Southern Tanzania: Effect of iodised oil on thyroid hormone deficiency. J Epidemiol Community Health. 1986.
[15]
Kalk WJ, Sitas F, Patterson AC. Thyroid cancer in South Africa--an indicator of regional iodine deficiency. S Afr Med J. 1997; 87 (6): 735–8.
[16]
Sirveaux F, Brunaud L, Klein M, Muresan MM, Olivier P, Lecle J. Bone metastases from differentiated thyroid carcinoma. 2008; 37–49.
[17]
Schlumberger MJ. Papillary and Follicular Thyroid Carcinoma. N Engl J Med. 1998; 338 (5): 297–306.
[18]
Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994.
[19]
Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006.
[20]
Haugen BR, Kane MA. Approach to the thyroid cancer patient with extracervical metastases. Journal of Clinical Endocrinology and Metabolism. 2010.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186